Sanofi licenses Owkin's AI scientist for a five-year biopharma-agent program

Owkin and Sanofi are moving their existing AI partnership from targeted analytics toward agentic drug research. Under a newly announced multi-year collaboration, Owkin will lead development of biopharma agents purpose-built for Sanofi, while Sanofi receives a five-year license for K Pro, Owkin's AI scientist. The agents are intended to autonomously perform complex research and development tasks using Owkin's multimodal patient-data network and biology models. The companies have worked together since 2021 through a EUR90 million strategic partnership focused on oncology target identification, patient subgrouping, and later drug positioning for immunology. This remains a company-announced development program, not evidence that autonomous agents have improved a medicine or clinical outcome. Its significance is the duration and scope: a major drugmaker is committing to agentic AI as research infrastructure rather than a short pilot.

Key details: June 5, 2026, Five-year K Pro license, Multi-year collaboration, Sanofi, Owkin, Existing EUR90M partnership.

Continue swiping for more AI Brief stories.